海栖热袍菌极耐高温木聚糖酶基因xynB64在大肠杆菌中的融合表达

来源于极端嗜热菌海栖热袍菌(Thermotoga maritima MSB8)的木聚糖酶B具有极高的热稳定性,在饲料、造纸、能源和食品医药行业具有巨大应用潜力。携带酶基因xynB64的pET28a(+)重组载体在宿主大肠杆菌BL21(DE3)中诱导表达,重组酶活力较低。更换宿主为携带稀有tRNA基因的大肠杆菌:BL21-CodonPlus(DE3)-RIPL和Rosetta(DE3)后,酶活力分别提高了197%和277%,但是后者中的表达会形成部分包涵体。宿主菌为大肠杆菌Rosetta(DE3),更换载体为4种融合表达载体pET32a(+)、pET42a(+)、pET43.1a(+)和pMAL-c2X进行表达,重组酶分别融合了Trx、GST、Nus和MBP标签。其中Rosetta(DE3)/pMAL-c2X-xynB64表达酶活力最高,相当于Rosetta(DE3)/pET28a-xynB64表达酶的88%,而且目的酶表达量占全细胞蛋白的40%,几乎不形成包涵体。     

抗黄曲霉毒素B1单链抗体在大肠杆菌中的表达及优化

摘要：【目的】继杂交瘤技术后,重组抗体技术是新一代的抗体制备技术。然而如何用原核系统中较多地表达具有生物活性的单链抗体,避免包涵体形成仍是一个需要探讨的问题。【方法】将目的基因scFv-H4克隆到载体pET22b上,分别转入大肠杆菌BL21（DE3）和Origami（DE3）中,通过改变诱导温度和IPTG浓度,比较具有生物活性的蛋白量以及包涵体的量。【结果】在BL21（DE3）中,pET22b能产生大量表达scFv-H4,而BL21(DE3) 的含有trxA和gor双突变的衍生菌Origami（DE3）表达的scFv-H4的总量较少,但是具有生物活性的蛋白量较多（35 mg/L培养物）,具有生物活性的蛋白比例也较BL21（DE3）高。另外IPTG的浓度对scFv-H4表达没有显著影响,而较高的诱导温度会促使表达的蛋白形成包涵体。【结论】在较低的温度下,pET22b能在Origami（DE3）能较好地表达具有生物活性的scFv-H4,减少包涵体的比例,为后续的抗体性质研究和改造奠定了基础。     

人C反应蛋白在不同原核表达载体及菌株中的表达及免疫反应性分析

构建人C反应蛋白(CRP)原核表达载体,并分别将其转化进入E.coli BL21(DE3)和Rosetta gami 2(DE3)p Lys S中,诱导CRP重组蛋白的表达;主要运用了基因工程,亲和层析及透析复性等方法。成功构建了CRP原核表达载体及菌株。经IPTG诱导后,得到了不同的重组CRP蛋白。结果表明,相同表达载体在不同的表达菌株中的表达情况有一定差别,分别在大肠杆菌及Rosetta gami2(DE3)p Lys S中表达并得到了重组CRP的包涵体,对复性后的CRP重组蛋白进行Westen blotting及ELISA检测,结果表明原核表达的重组CRP蛋白的免疫反应性很低,CRP蛋白发挥免疫活性需要以五聚体形式存在。     

D-氨基酸氧化酶与麦芽糖结合蛋白和透明颤菌血红蛋白的融合表达

D-氨基酸氧化酶(DAAO)是一种重要的工业酶。为了进一步提高DAAO在大肠杆菌中的可溶性和活性表达, 分别构建了麦芽糖结合蛋白(MBP)和透明颤菌血红蛋白与三角酵母DAAO (TvDAAO) 的N-端融合蛋白。其中, MBP融合蛋白MBP-TvDAAO在组成型(JM105/pMKC-DAAO)和诱导型菌株(JM105/pMKL-DAAO)中表达时, 目标蛋白的可溶性表达量分别达到全细胞蛋白表达量的28%以上和17%左右, 比无MBP融合的对照菌株BL21(DE3)/pET-DAAO分别提高3.7和1.8倍; 但其酶活水平显著下降。VHb融合蛋白VHb-TvDAAO在重组菌BL21(DE3)/pET-VDAAO中摇瓶诱导表达时, DAAO酶活达到了3.24 u/mL, 比对照菌株BL21(DE3)/pET-DAAO提高了约90%。     

D-氨基酸氧化酶与麦芽糖结合蛋白和透明颤菌血红蛋白的融合表达

D-氨基酸氧化酶(DAAO)是一种重要的工业酶。为了进一步提高DAAO在大肠杆菌中的可溶性和活性表达, 分别构建了麦芽糖结合蛋白(MBP)和透明颤菌血红蛋白与三角酵母DAAO (TvDAAO) 的N-端融合蛋白。其中, MBP融合蛋白MBP-TvDAAO在组成型(JM105/pMKC-DAAO)和诱导型菌株(JM105/pMKL-DAAO)中表达时, 目标蛋白的可溶性表达量分别达到全细胞蛋白表达量的28%以上和17%左右, 比无MBP融合的对照菌株BL21(DE3)/pET-DAAO分别提高3.7和1.8倍; 但其酶活水平显著下降。VHb融合蛋白VHb-TvDAAO在重组菌BL21(DE3)/pET-VDAAO中摇瓶诱导表达时, DAAO酶活达到了3.24 u/mL, 比对照菌株BL21(DE3)/pET-DAAO提高了约90%。     

TAT-hEGF融合蛋白在E.coli BL21(DE3)中高效自我表达

为了获得TAT-hEGF融合蛋白在E.coliBL21(DE3)中高效表达,构建了原核表达载体pRSET-tat-hegf,将其转化E.coliBL21(DE3)得到重组工程菌BL21(DE3)/pRSET-tat-hegf。工程菌在无IPTG的诱导下实现了高效表达,TAT-hEGF融合蛋白的表达量占总菌体蛋白的45.6%,主要以包涵体形式存在。     

霍乱弧菌zot基因的克隆及其在大肠杆菌中的表达

从霍乱疫苗菌中抽提基因组DNA,用PCR的方法扩增zot基因。序列分析表明,zot基因编码399个氨基酸,其中4个氨基酸与文献报道有差异。将zot基因插入含T7启动子的质粒pET28(a+)构建表达质粒pET-ZOT,转化大肠杆菌BL21(DE3)筛选表达菌株BLZOT。表达菌株经1mmol/L IPTG诱导表达3～5h后,表达大量ZOT蛋白,并形成包涵体。经SDS-PAGE分析重组ZOT蛋白分子量约为47kD,凝胶自动扫描分析表明,重组ZOT约占菌体可溶性蛋白量的15%以上。本工作为进一步研究蛋白多肽类药物的口服奠定了良好的基础。     

产普鲁兰酶重组大肠杆菌质粒稳定性的研究

通过对产普鲁兰酶的重组大肠杆菌E.coli BL21(DE3)/p ET28a-s-pul菌株在发酵过程中质粒稳定性和普鲁兰酶生成量的考察,发现不同宿主对质粒稳定性及酶活性有重要影响。本文利用E.coli BL21(DE3)p Lys S菌株为宿主,构建重组菌E.coli BL21(DE3)p Lys S/p ET28a-s-pul,通过控制外源蛋白的本底表达,提高了重组菌株的质粒稳定性。优化发酵培养基和发酵条件以后,重组菌产普鲁兰酶能力由480 U/m L提高至627 U/m L,增幅为30.6%。研究结果认为,严格控制外源蛋白的本底表达,是改善重组菌稳定性的重要方法之一。     

重组N-乙酰鸟氨酸脱乙酰基酶的表达、纯化和复性研究

报道重组N-乙酰鸟氨酸脱乙酰基酶(NAOase)的研究进展。重组NAOase由大肠杆菌argE基因编码,在重组菌BL21(DE3)-pET22b-argE中的表达量为32.5%,大多以无活性的包涵体存在。低温诱导可增大有活性的可溶表达部分的比例。可溶性NAOase经Ni-NTA凝胶亲和纯化后得到SDS-PAGE电泳纯的酶,比酶活为1193.2u/mg蛋白。诱导条件影响整菌蛋白的成分及比例。37℃诱导生成的包涵体经尿素梯度洗涤后纯度较22℃高。低的蛋白浓度和合适的氧化还原体系是影响复性的关键因素。稀释法和透析法皆可使包涵体部分复性。在合适的条件下以稀释法复性时,约有17.78%包涵体可顺利复活。包涵体经尿素洗涤、溶解、Ni-NTA凝胶柱亲和纯化后,获得了高纯度的NAOase。     

猪瘟病毒E0蛋白的原核表达及其间接ELISA方法的建立

表达猪瘟病毒保护性抗原E0蛋白用以建立猪瘟抗体诊断方法,在标记疫苗(Marker vaccine)的研制和应用上具有重要的血清学鉴别功能,对于监测猪瘟病毒的流行情况和疫苗免疫情况及制定免疫程序具有重要作用.将猪瘟兔化弱毒株(HCLV)E0基因分别插入原核表达质粒pGEX4T,pET30,pMAL-p2X中,并分别以BL21和BL21-codonplus(DE3)-RP, BL21(DE3)和BL21-codonplus(DE3)-RP,TB1和BL21-codonplus(DE3)-RP为表达菌株.通过摸索IPTG诱导浓度,诱导温度,菌体收获时间,确定E0基因能在pGEX4T/ BL21-codonplus(DE3)-RP和pMAL-p2X/ BL21-codonplus(DE3)-RP中获得高效表达,表达产量分别占菌体总蛋白的15%和30%,表达的重组蛋白主要为包涵体形式.分别采用B-per试剂和超声波裂解配以曲通尿素对包涵体进行洗涤两种方法在pGEX表达系中取得了较好的效果.使用分步透析法对变性的包涵体进行复性,将复性蛋白过GST亲和层析柱得到纯化的GST-E0融合蛋白.以GST-E0融合蛋白为诊断抗原,通过摸索抗原包被浓度,抗体血清稀释倍数初步建立了用间接ELISA检测猪瘟血清E0抗体的方法,为进一步开发猪瘟抗体检测试剂盒奠定基础.     

动物细胞双顺反子高效稳定表达系统建立

建立稳定高效的动物细胞表达系统对于许多重组蛋白质药物的工业化生产有着十分重大的意义。用PCR扩增得到dhfr基因 ,克隆入载体pIRESneo3基因以替换原有的neo^r 基因 ,并将hbFGF作为报告基因插入其多克隆位点 ,得到重组子pIRESdhfr hbFGF ,转导CHO细胞后 ,MTX浓度梯度筛选稳定表达hbFGF的细胞株 ,ELISA与WesternBlot检测培养基中hbFGF的分泌表达。结果发现10、100、1000nmol LMTX组均检测到hbFGF的表达 ,其中表达量最高的一株细胞传代20次后表达量仍能维持较高的水平。因此利用双顺反子表达系统可以实现外源基因在动物细胞中的高效稳定表达 。     

Highly efficient soluble expression and purification of recombinant human basic fibroblast growth factor (hbFGF) by fusion with a new collagen-like protein (Scl2) in Escherichia coli

Abstract

Human basic fibroblast growth factor (hbFGF) is involved in a wide range of biological activities that affect the growth, differentiation, and migration. Due to its wound healing effects and therapy, hbFGF has the potential as therapeutic agent. Therefore, large-scale production of biologically active recombinant hbFGF with low cost is highly desirable. However, the complex structure of hbFGF hinders its high-level expression as the soluble and functional form. In the present study, an efficient, cost-effective, and scalable method for producing recombinant hbFGF was developed. The modified collagen-like protein (Scl2-M) from Streptococcus pyogenes was used as the fusion tag for producing recombinant hbFGF for the first time. After optimization, the expression level of Scl2-M-hbFGF reached approximately 0.85?g/L in the shake flask and 7.7?g/L in a high cell-density fermenter using glycerol as a carbon source. Then, the recombinant Scl2-M-hbFGF was readily purified using one-step acid precipitation and the purified Scl2-M-hbFGF was digested with enterokinase. The digested mixture was further subject to ion-exchange chromatography, and the final high-purity (96%) hbFGF product was prepared by freeze-drying. The recovery rate of the whole purification process attained 55.0%. In addition, the biological activity of recombinant hbFGF was confirmed by using L929 and BALB/c3T3 fibroblasts. Overall, this method has the potential for large scale production of recombinant hbFGF.     

人碱性成纤维细胞生长因子突变体的高效表达

用PCR法将人碱性成纤维细胞生长因子(hbFGF)基因中编码第25、69和92位的半胱氨酸(Cys)密码子突变为丝氨酸(Ser)密码子,将突变的hbFGFcDNA片断与表达质粒pET3c连接,构建重组质粒pET3chbFGFSer25,69,92。hbFGFSer25,69,92在大肠杆菌BL21(DE3)中的表达量大于30%。通过阳离子交换和肝素亲和层析两步纯化,得到纯度大于95%的hbFGFSer25,69,92。MTT法测定纯化的产物活性表明,hbFGFSer25,69,92突变体促Balb/c细胞增殖的活性与野生型hbFGF相当,为下一步对hbFGFSer25,69,92突变体进行定点化学修饰打下了基础。     

一种促分裂活性降低的hbFGF突变体的表达及纯化(英文)

为了降低由人碱性成纤维细胞生长因子(hbFGF)的广谱促分裂活性引起的潜在副作用,用中性氨基酸丙氨酸取代了hbFGF第108位的丝氨酸,构建了促分裂活性降低的hbFGF突变体(mhbFGF)。IPTG诱导突变体在大肠杆菌BL21(DE3)中高效表达。mhbFGF的表达量约为全菌体蛋白的30％。通过离子交换和肝素亲和层析从菌体上清中纯化目标蛋白。MTT法检测促分裂活性表明,mhbFGF的促分裂活性显著低于野生型hbFGF。纯化的:mhbFGF可用于进一步的药效和安全性研究。     

使用一种新策略在大肠杆菌中高效表达hbFGF

翻译起始区（TIR）二级结构是影响翻译效率的决定性因素,同时密码子的偏好性问题也是个至关重要的方面。基于以上两点考虑,对hbFGF5‘末端35个碱基进行了改造,对其中4个位点进行了定点突变,另有4个位点进行了随机点突变。这些突变都可能造成TIR二级结构变化。这4个随机突变共有32种组合,使用RNA结构预测软件DNASIS v2.5对这32种序列分别模拟其二级结构且计算其自由能,并选取了10条自由能最高的序列。根据这10条序列,分别设计引物引入突变,克隆至表达载体pET-3c上,然后转化宿主菌E.coli,通过诱导表达纯化及生物测活等常规实验方法,最后确定有两株为高表达菌株,从某种程度上证明了用计算机辅助设计定点突变的方法来优化外源基因在E.coli中的表达是有效且很有潜力的。     

重组人碱性成纤维细胞生长因子在大肠杆菌中的高效表达*

利用基因改造的方法可以优化外源基因在大肠杆菌中的表达。利用逆转录PCR技术从原代培养的人成纤维细胞中克隆出人碱性成纤维细胞生长因子基因,在不改变氨基酸序列的前提下对该基因的上游部分序列进行改造,并将其插入表达载体pET-3c,转入大肠杆菌阳BL21（DE3）,IPTG诱导表达,表达蛋白占菌体总蛋白的30％以上,并具有良好的生物活性。     

Positive Effects of bFGF Modified Rat Amniotic Epithelial Cells Transplantation on Transected Rat Optic Nerve

PurposeEffective therapy for visual loss caused by optic nerve injury or diseases has not been achieved even though the optic nerve has the regeneration potential after injury. This study was designed to modify amniotic epithelial cells (AECs) with basic fibroblast growth factor (bFGF) gene, preliminarily investigating its effect on transected optic nerve.MethodsA human bFGF gene segment was delivered into rat AECs (AECs/hbFGF) by lentiviral vector, and the gene expression was examined by RT-PCR and ELISA. The AECs/hbFGF and untransfected rat AECs were transplanted into the transected site of the rat optic nerve. At 28 days post transplantation, the survival and migration of the transplanted cells was observed by tracking labeled cells; meanwhile retinal ganglion cells (RGCs) were observed and counted by employing biotin dextran amine (BDA) and Nissl staining. Furthermore, the expression of growth associated protein 43 (GAP-43) within the injury site was examined with immunohistochemical staining.ResultsThe AECs/hbFGF was proven to express bFGF gene and secrete bFGF peptide. Both AECs/hbFGF and AECs could survive and migrate after transplantation. RGCs counting implicated that RGCs numbers of the cell transplantation groups were significantly higher than that of the control group, and the AECs/hbFGF group was significantly higher than that of the AECs group. Moreover GAP-43 integral optical density value in the control group was significantly lower than that of the cell transplantation groups, and the value in the AECs/hbFGF group was significantly higher than that of the AECs group.ConclusionsAECs modified with bFGF could reduce RGCs loss and promote expression of GAP-43 in the rat optic nerve transected model, facilitating the process of neural restoration following injury.     

原核表达hbFGF结构与功能优化的研究

野生型hbFGF蛋白可溶性与稳定性较低一直是困扰研发人员的难题。分析其氨基酸序列发现含有 4个游离巯基 ,其中第 78、96、1 0 1位半胱氨酸游离巯基可能直接影响其可溶性、稳定性及活性。对天然hbFGF进行定点突变 ,一组将Cys78、Cys96同时突变 ,另一组将Cys78、Cys96与Cys1 0 1进行联合突变 ,均改为丝氨酸密码子 ,然后克隆入原核表达载体pET 3c ,进行表达 ,结果发现两种突变蛋白的可溶性大幅度增加 ,稳定性明显上升 ,其中三点突变的效果更为显著 ,但蛋白质的活性明显下降。可以认为 78、96与 1 0 1位半胱氨酸的游离巯基同时参与了天然hbFGF多聚体的形成 ,是导致野生型hbFGF可溶性与稳定性较低的主要原因 ,Cys1 0 1还与维持hbFGF的活性直接有关     

Differential expression of human basic fibroblast growth factor in Escherichia coli: potential role of promoter

Four different expression systems were developed for expression of the cDNA encoding human basic fibroblast growth factor (hbFGF), using Escherichia coli as host organism. The hbfgf structural gene was cloned into four expression vectors, pET-3a, pTrc99A, pPR37 and pKK223-3 differing only in their promoters, which were T7, trc, PR and tac respectively. Expression of the gene was induced by adding 0.5 mM (final concentration) of isopropyl--D-thio-galactopyranoside (IPTG) for the vectors carrying T7, trc and tac promoters or by a temperature shift from 30 to 42 °C for the vector carrying PR. The highest level of expression was observed in pET-1005 (a pET-3a derivative)/BL21 (DE3) system with 18.5 mg/l rhbFGF and the second high level expression was in pR37-1007 (pPR37 derivative) BL21 (DE3) system with 5 mg of rhbFGF/l. Since in the latter system a temperature shift was used for induction, 29% of the hbFGF was recovered as inclusion bodies in the insoluble cell fraction. The level of expression for the two other systems (pTrc-1006 and pKK-1008) was very low.     

Site-directed PEGylation of human basic fibroblast growth factor

Through site-directed mutagenesis, three cysteines of human basic fibroblast growth factor (hbFGF) were replaced with serine residues, resulting in a hbFGF mutant named hbFGFSer25,69,92. The mutant with only one cysteine residue at the 87th position, whose mitogenic activity was comparable to that of wild-type hbFGF, was further coupled to polyethylene glycol with a molecular size of 5 kDa (PEG5K) via the cysteine residue to obtain another hbFGF derivative, PEG5K-hbFGFSer25,69,92. The optimal modification reaction was conducted at 4 degrees C for 4 h at a molar ratio of PEG5K to hbFGFSer25,69,92 of 20:1. The result of SDS-PAGE showed that the modification extent was up to 80%. The modified product was purified by ion exchange chromatography. Compared to the hbFGF mutant, the purified PEG5K-hbFGFSer25,69,92 still retained about 60% of the mitogenic activity of the former, which provided a good basis for further studying the bioactivity of the PEGylated protein in vivo.